A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis

• Main Authors: Fu-Yao Jiang (Author), Yan-Zhu Zhang (Author), Yuan-Hong Tai (Author), Chien-Yu Chou (Author), Yu-Ching Hsieh (Author), Ya-Chi Chang (Author), Hsiao-Chen Huang (Author), Zhi-Qin Li (Author), Yuan-Chin Hsieh (Author), I-Ju Chen (Author), Bo-Cheng Huang (Author), Yu-Cheng Su (Author), Wen-Wei Lin (Author), Hsin-Chieh Lin (Author), Jui-I Chao (Author), Shyng-Shiou F. Yuan (Author), Yun-Ming Wang (Author), Tian-Lu Cheng (Author), Shey-Cherng Tzou (Author)
• Format: Book
• Published: BMC, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background CTLA4Ig is a dimeric fusion protein of the extracellular domain of cytotoxic T-lymphocyte protein 4 (CTLA4) and an Fc (Ig) fragment of human IgG1 that is approved for treating rheumatoid arthritis. However, CTLA4Ig may induce adverse effects. Developing a lesion-selective variant...